Strategic partnership with Boston Micro Fabrication, providing access to micro-precision printing technology.
Differentiation
Value Proposition
Enabling precise, potentially painless delivery of therapeutics and cosmetics via advanced dissolvable microneedles manufactured with high-resolution 3D printing.
How They Differentiate
Focus on ultra-high resolution 3D printing through a strategic collaboration with Boston Micro Fabrication, allowing for unique geometries not attainable with conventional manufacturing.
["Announced strategic investment and collaboration with Boston Micro Fabrication (May 2024)", "Acquired Focal Medical, a North Carolina-based iontophoresis drug-delivery company with FDA IND clearance for a pancreatic cancer (gemcitabine) candidate (June 4, 2025)"]
Notable Customers
Breakthrough T1D; Houston Methodist Hospital; Miami School of Medicine
Continuity Biosciences is developing a biofabrication platform for combination products that combine drug or cosmetic formulations with advanced delivery mechanisms. The company focuses on dissolvable microneedle patches manufactured via ultra-high-resolution polymer 3D printing, aiming to enable precise, potentially painless delivery of therapeutics and cosmetics. This approach targets a gap in conventional microneedle manufacturing, which typically relies on molding or other methods that limit geometric complexity.
The core technology leverages microdispensing and micro-precision printing through a strategic partnership with Boston Micro Fabrication. This collaboration provides access to high-resolution additive manufacturing capable of producing complex microneedle geometries not achievable with traditional fabrication. The company has also licensed several technology platforms from Houston Methodist Hospital, including nanofluidic systems for drug delivery, cell storage systems for stem cell transplantation and immune modulation, the NICHE platform for Type 1 Diabetes, and an iontophoretic system for intratumoral delivery in oncology.
Target customers include pharmaceutical and cosmetic companies seeking innovative delivery solutions. Notable partners and customers include Breakthrough T1D, Houston Methodist Hospital, and Miami School of Medicine. The company serves the pharmaceuticals and cosmetics verticals, with applications ranging from vaccine delivery to skincare. Competitors include Vaxxas, Raphas, and Kindeva Drug Delivery, though Continuity differentiates through its focus on ultra-high-resolution 3D printing for unique microneedle geometries.
Founded in 2024 and based in Bradenton, FL, the company is led by CEO Ramakrishna Venugopalan, a former AbbVie senior executive specializing in drug delivery for products including Skyrizi. Continuity raised $9.42M in funding, with Boston Micro Fabrication as a key investor. The company announced a strategic investment and collaboration with Boston Micro Fabrication in May 2024. A key open question is whether its microdispensing platform can scale from pilot production to commercial volumes required by pharmaceutical and cosmetic partners.